Integrated efficacy analysis from phase 3 studies of investigational microbiome therapeutic, SER-109, in recurrent Clostridioides difficile infection

por Sims, Matthew, Silverman, Michael, Louie, Thomas, Wang, Elaine, Kraft, Colleen, Ramesh, Mayur, Bogdanovich, Tatiana, Brady, Kelly, Lombardi, David, Memisoglu, Asli, De, Ananya, Hasson, Brooke, Lee, Christine, Feuerstadt, Paul, Pardi, Darrell, Kelly, Colleen, Daley, Peter, Oguchi, Godson, McGovern, Barbara, Moltke, Lisa Von
Publicado 2023

Integrated safety analysis of phase 3 studies for investigational microbiome therapeutic, SER-109, in recurrent CDI

por Sims, Matthew, Berenson, Charles, Cohen, Stuart, Wang, Elaine, Hohmann, Elizabeth, Nathan, Richard, Odio, Alberto, Cook, Paul, Brady, Kelly, Lombardi, David, Memisoglu, Asli, De, Ananya, Hasson, Brooke, Lashner, Bret, Korman, Louis, Grimard, Doria, Gutierrez, Juan Carlos Moises, McGovern, Barbara, Moltke, Lisa Von
Publicado 2023